Spirapril
Spirapril is a prodrug angiotensin-converting enzyme (ACE) inhibitor that is hydrolyzed to its active form spiraprilat, used for the treatment of hypertension and heart failure, with investigational properties in stroke prevention. By inhibiting ACE-mediated conversion of angiotensin I to angiotensin II, it reduces vasoconstriction, aldosterone secretion, and sodium retention, lowering blood pressure and cardiac preload and afterload. It has a long duration of action allowing once-daily dosing.
Berat Molekul
466,6000 g/mol
LogP
0,90
TPSA
147,00 Ų
Lipinski RO5
Lulus
Area Terapeutik
Mekanisme Kerja
Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.
Struktur 2D
Cite this structure
Embed this structure
SMILES
CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1CC2(C[C@H]1C(=O)O)SCCS2
InChI
InChI=1S/C22H30N2O5S2/c1-3-29-21(28)17(10-9-16-7-5-4-6-8-16)23-15(2)19(25)24-14-22(30-11-12-31-22)13-18(24)20(26)27/h4-8,15,17-18,23H,3,9-14H2,1-2H3,(H,26,27)/t15-,17-,18-/m0/s1
Molecular Formula
C22H30N2O5S2
HBD / HBA
2 / 8
Ikatan yang Dapat Dirotasi
10
Atom Berat
31
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Pertanyaan yang Sering Diajukan
Spirapril is a prodrug angiotensin-converting enzyme (ACE) inhibitor that is hydrolyzed to its active form spiraprilat, used for the treatment of hypertension and heart failure, with investigational properties in stroke prevention. By inhibiting ACE-mediated conversion of angiotensin I to angiotensin II, it reduces vasoconstriction, aldosterone secretion, and sodium retention, lowering blood pressure and cardiac preload and afterload. It has a long duration of action allowing once-daily dosing.
Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.
Yes, Spirapril is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL431. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 5311447. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="spirapril"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/spirapril/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/spirapril/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/spirapril/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="spirapril"></drugfyi-drug>